Effectiveness of Mineral Trioxide Aggregate and Platelet Rich Fibrin Along With Biodentine. .
Condition: Pulpitis - Irreversible
MeSH terms: Pulpitis
Study type: Interventional
Phase: Phase 4

Summary: 
      The aim of this study was to clinically and radiographically evaluate the effectiveness of
      MTA, Biodentine, Platelet Rich Fibrin along with Mineral Trioxide Aggregate and Platelet Rich
      Fibrin along with Biodentine as pulpotomy medicament in patients with pulpitis.
    

Detailed description: 
      Sixty systemically healthy patients with irreversible pulpitis were enrolled in the study
      based on inclusion and exclusion criteria. All the enrolled patients were randomly allocated
      into 4 groups (15 each)

      Group I: MTA GROUP: Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as
      pulp capping agent. Group II: BIODENTINE GROUP: Vital Pulpotomy will be done using Biodentine
      as pulp capping agent. Group III: PRF + MTA GROUP: Vital Pulpotomy will be done using PRF and
      Mineral trioxide aggregate (MTA) as pulp capping agent. Group IV: PRF+ BIODENTINE GROUP:
      Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent Patients were
      assessed at 1 day,3 months, 6 months and 9 months postoperatively for pain, pulp sensitivity
      test, swelling or presence of any sinus tract. All the proposed teeth were assessed
      radiographically at1 day, 3 months, 6 months and 9 months postoperatively.
    

Intervention name(s): Mineral trioxide aggregate; Biodentine; Platelet rich fibrin
Intervention type(s): Drug; Drug; Biological
Intervention description(s): Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent; Vital Pulpotomy will be done using Biodentine as pulp capping agent; 10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit.
The product obtained after centrifugation consisted of three layers:
Acellular platelet plasma- top most layer
Platelet rich fibrin -middle layer
Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece
Other intervention name(s): MTA; Biodenine
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Sixty systemically healthy patients with irreversible pulpitis were enrolled in the study based on inclusion and exclusion criteria. All the enrolled patients were randomly allocated into 4 groups (15 each)
Group I: MTA GROUP: Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent. Group II: BIODENTINE GROUP: Vital Pulpotomy will be done using Biodentine as pulp capping agent. Group III: PRF + MTA GROUP: Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent. Group IV: PRF+ BIODENTINE GROUP: Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent.
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Keywords: pulpal regeneration; pulpitis; pulpotomy